Celiac Diseases Drugs Market 2024-2028: Size and Poor diagnosis; growth driven by the Therapy, Some of key Companies Positioned Strategically

The celiac diseases drugs market size by Therapy (First line treatment and Second-line treatment), Route Of Administration (Oral and Parenteral), and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 1101.1 million. The market is expected to grow at a CAGR of  almost 21.21% between 2024 and 2028.

• Celiac disease, an autoimmune disorder, presents complex diagnostic challenges due to its nonspecific symptoms and the lack of a definitive biomarker. This results in a significant number of misdiagnoses and undetected cases, with estimates suggesting that up to eight out of ten individuals remain undiagnosed. The disease can manifest at any age, with the average age of diagnosis for adults being between 30 and 50. The lengthy diagnostic process, which can last up to eleven years on average, underscores the need for improved diagnostic tools and effective treatment options in the celiac disease drugs market.
• The Celiac Diseases Drugs Market represents a significant business opportunity due to the rising prevalence of celiac disease and growing awareness of gluten-intolerance. Key players in this market include Alvogen, Dr. Reddy's Laboratories, and Intas Pharmaceuticals, who are developing and marketing gluten-free drugs to cater to this niche patient population. Market growth is driven by increasing diagnoses, regulatory approvals, and advancements in drug technology.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• 9 Meters Biopharma Inc
• Adaptive Biotechnologies Corp.
• Almirall SA
• Amgen Inc.
• AMYRA Biotech AG
• Artielle Immunotherapeutics Inc
• Avaxia Biologics Inc.
• BioLineRx Ltd.
• Bristol Myers Squibb Co.
• Calypso Biotech BV
• GlaxoSmithKline Plc
• Glenmark Pharmaceuticals Ltd.
• ImmunogenX Inc.
• Johnson and Johnson Services Inc.
• Precigen Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Vactech Oy
• Zedira GmbH

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/